Impact of Halobetasol Propionate and Tazarotene Lotion 0.01%/0.045% in the Management of Plaque Psoriasis in Adults

Documenti analoghi

• Impact of Halobetasol Propionate and Tazarotene Lotion 0.01%/0.045% in the Management of Plaque Psoriasis in Adults
  di: Reddy, Vidhatha, et al.
  Pubblicazione: (2020)
• Halobetasol 0.01%/Tazarotene 0.045% Fixed-combination Lotion in the Treatment of Plaque Psoriasis: Sensitization and Irritation Potential
  di: Del Rosso, James Q., et al.
  Pubblicazione: (2019)
• Safety and Efficacy of a Halobetasol 0.01%/Tazarotene 0.045% Fixed Combination Lotion in the Treatment of Moderate-to-severe Plaque Psoriasis: A Comparison with Halobetasol Propionate 0.05% Cream
  di: Bhatia, Neal D., et al.
  Pubblicazione: (2018)
• Tazarotene 0.045% Lotion for Moderate-to-Severe Acne in Male and Female Participants: A Phase II Post-hoc Analysis
  di: Baldwin, Hilary E., et al.
  Pubblicazione: (2021)
• Bioavailability, Pharmacokinetics, and Transepidermal Water Loss of Short Contact Tazarotene Lotion 0.1% Versus Tazarotene (Tazorac(®)) Cream 0.1%
  di: Sidgiddi, Srinivas, et al.
  Pubblicazione: (2019)